Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company’s chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019.
It is with great sadness that the company has learned of the passing of Dr. Martin, whose scientific vision and leadership helped transform the lives of millions of patients and shape Gilead into the company that it is today. John began his career at Gilead in 1990, as vice president of Research & Development. As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth.
“John’s legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “On behalf of all of us at Gilead, I extend our deepest condolences to John’s family.”
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210330006163/en/
Jacquie Ross, Investors
(650) 358-1054
Amy Flood, Media
(650) 522-5643